March 2011
425
duce delayed contact hypersensitivity at the maximum con- REFERENCES
centration of 10%.
1) Urabe K., Nakayama J., Hori Y., “The Pigmentary System: Physiology
and Pathophysiology,” ed. by Norlund J. J., Boissy R. E., Hearing V. J.,
King R. A., Ortonne J. P., Oxford University Press, New York, 1998,
pp. 909—911.
2) Cullen M. K., “The Pigmentary System: Physiology and Pathophysiol-
ogy,” ed. by Norlund J. J., Boissy R. E., Hearing V. J., King R. A., Or-
tonne J. P., Oxford University Press, New York, 1998, pp. 760—766.
3) Maeda K., Fukuda M., J. Pharmacol. Exp. Ther., 276, 765—769
(1996).
Finally, we examined skin penetration of compound 1
using in vitro method. Formulations containing different con-
centrations of compound 1 was applied onto the skin surface.
As shown in Fig. 3, the amount of the compound 1 deter-
mined after tissue extraction increased according to the con-
centration of the product applied onto the surface of the skin.
These data indicated that compound 1 could diffuse across
cutaneous tissue at up to 0.5% in formulation.
4) Battaini G., Monzani E., Casella L., Santagostini L., Pagliarin R., J.
Biol. Inorg. Chem., 5, 262—268 (2000).
5) Masamoto Y., Murata Y., Baba K., Shimoishi Y., Tada M., Takahata
K., Biol. Pharm. Bull., 27, 422—425 (2004).
CONCLUSION
6) Okombi S., Rival D., Bonnet S., Mariotte A. M., Perrier E., Boumen-
djel A., Bioorg. Med. Chem. Lett., 16, 2252—2255 (2006).
7) Sawabe A., Satake T., Aizawa R., Sakatani K., Nishimoto K., Ozeki
C., Hamada Y., Komemushi S., J. Oleo. Sci., 55, 413—422 (2006).
8) Le Mellay-Hamon V., Criton M., Biol. Pharm. Bull., 32, 301—303
(2009).
9) Fenoll L.G., Rodríguez-López J. N., Varón R., García-Ruiz P. A.,
García-Cánovas F., Tudela J., Biol. Chem., 381, 313—320 (2000).
10) Hill T., Odell L. R., Edwards J. K., Graham M. E., McGeachie A. B.,
Rusak J., Quan A., Abagyan R., Scott J. L., Robinson P. J., McCluskey
A., J. Med. Chem., 48, 7781—7788 (2005).
11) Pomerantz S. H., J. Biol. Chem., 238, 2351—2357 (1963).
12) Borenfreund E., Puerner J. A., Toxicol. Lett., 24, 119—124 (1985).
13) Siegrist W., Eberle A. N., Anal. Biochem., 159, 191—197 (1986).
14) Gordon P. R., Gilchrest B. A., J. Invest. Dermatol., 93, 700—702
(1989).
It can be concluded from this whole study that dimeric
cinnamoyl amide compounds are more efficient to inhibit ty-
rosinase activity than their monomeric counterparts. Indeed
dimeric derivatives of p-coumaric acid (compound 1) and of
isoferulic acid (compound 3) inhibit mushroom tyrosinase
activity (IC50ꢂ5.7 mM and IC50ꢂ8.5 mM respectively) more
potently than kojic acid. Evaluated on melanocytes com-
pound 1 can also reduce melanin production (melanoma cell
line and normal human melanocytes) more efficiently than
kojic acid. Further, our result indicate that the active com-
pound 1 is not mutagenic in vitro and do not induce neither
skin sensitisation nor irritation in vivo. Finally, we show that,
applied into skin formulated compound 1 can easily diffuse
in the epidermis and reach its site of action. All these results
lead us to propose that compound 1 may be a potential candi-
date for treating skin hyperpigmentation related disorders.
15) Ames B. N., McCann J., Yamasaki E., Mutat. Res., 31, 347—364
(1975).
16) Hayes B. B., Meade B. J., Drug Chem. Toxicol., 22, 491—506 (1999).
17) Kimber I., Dearman R. J., Scholes E. W., Basketter D. A., Toxicology,
93, 13—31 (1994).
18) Shi Y., Chen Q. X., Wang Q., Song K. K., Qiu L., Food Chem., 92,
707—712 (2005).
19) Liu S. H., Pan I. H., Chu I. M., Biol. Pharm. Bull., 30, 1135—1139
(2007).
Acknowledgments The authors are grateful to Dr.
Corine Bertolotto for reading this manuscript.